H3 Biomedicine

About H3 Biomedicine

H3 Biomedicine is a leading company in cancer genomics based drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million funding commitment from Eisai plus additional funding for clinical programs. As a clinical-stage biopharmaceutical company, we uniquely leverage our distinct insights from cancer genomics and real-life patient data to advance our projects to clinical proof of concept and beyond. H3 embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company to create a prolific drug discovery engine and partnership platform.

Click here to go to H3 Biomedicine's website.